Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eli Lilly (LLY) shares fell 2.3% Monday after a study conducted by the drug maker found patients who use its weight-loss treatments may gain weight once they stop taking the drugs.

Eli Lilly Stock Slips After Reported Weight Gain In Users Who Quit Its Drug

Patients using Eli Lilly's weight-loss drug Zepbound experienced a “substantial regain” of lost weight after withdrawing from treatment, according to a study published Monday, the latest study indicating withdrawal from weight-loss drugs could cause patients to regain lost weight.

Patients Who Stopped Using Zepbound Experienced ‘Substantial' Weight Regain, Eli Lily's Study Suggests

The data suggests that people have to stay on the weekly injection Zepbound if they want to maintain weight loss.

Patients regain weight after stopping Eli Lilly's Zepbound, study says

A JAMA study shows that patients who stopped taking Zepbound after 36 weeks on the drug experienced a 14% weight regain over a year.

Eli Lilly Stock Falls on Data That Show Patients Who Stopped Zepbound Regained Weight

Cigna

Humana

U.S. equities were little changed at midday ahead of key inflation data due later in the week and the final Federal Reserve policy meeting of 2023. The Dow and S&P 500 were up slightly, while the Nasdaq was in the red.

Midday Movers: Cigna Soars After Calling Off Humana Deal, Eli Lilly Falls Following Study

Eli Lilly & Co (NYSE: LLY) is down nearly 4.0% today after a study indicated that weight-loss from Zepbound tends to reverse once the treatment is stopped. Patients regain weight if they stop taking Zepbound Zepbound helped patients lose close to 21% of their weight on average in about 36 weeks.

Here's what will happen if you stopped taking Eli Lilly's weight-loss drug

Individuals using Eli Lilly and Co (NYSE:LLY)'s obesity drug Zepbound (tirzepatide) regained weight after they stopped using the treatment, according to a study published Monday in the Journal of the American Medical Association (JAMA). Patients using the drug lost an average of 20.9% of their body weight in nine months, the study showed.

Eli Lilly obesity drug patients regained weight after ending treatment: study

Eli Lilly stock skidded Monday after a new study showed patients who stopped taking its weight-loss drug slowly regained weight over a year.

Eli Lilly Skids, Weighing On Novo Nordisk, On A Key New Finding For Obesity Drugs

Patients on Eli Lilly's weight-loss drug trial substantially regained weight after stopping treatment, according to a study published in journal JAMA on Monday.

Patients on Eli Lilly's drug regain weight after stopping treatment - JAMA study

People who were randomized to placebo following the lead-in period experienced mean weight regain of 14.8% at 88 weeks, indicating Zepbound led to sustained weight loss compared to placebo Full results from the SURMOUNT-4 study were published in The Journal of the American Medical Association INDIANAPOLIS , Dec. 11, 2023 /PRNewswire/ -- Detailed results from SURMOUNT-4, which showed Zepbound™ (tirzepatide) injection achieved superior mean percent change in body weight compared to placebo in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes, were published in The Journal of the American Medical Association (JAMA) . Zepbound met the primary endpoint of mean percent change in body weight, and all key secondary endpoints for both estimandsi,ii, compared to placebo 52 weeks after randomization.

Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks

Broadcom

JPMorgan Chase & Co

Taiwan Semiconductor Manufacturing

UnitedHealth Group

Visa

As 2024 unfolds, the spotlight falls on identifying the next trillion-dollar stocks. This elite club, currently consisting of six corporate giants at this time, symbolizes financial might, market influence, and innovative prowess.

Future Trillion-Dollar Companies: 7 Stocks to Invest in Now

Axsome Therapeutics

Vertex Pharmaceuticals

Axsome is bringing in consistent revenue and has significant upside potential. Eli Lilly is the world's biggest drugmaker and stands to grow even more.

3 Unstoppable Stocks to Buy Right Now

The latest trading day saw Eli Lilly (LLY) settling at $598.05, representing a +1.66% change from its previous close.

Eli Lilly (LLY) Rises Higher Than Market: Key Facts

INDIANAPOLIS, Dec. 8, 2023 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15% increase in its quarterly dividend and declared a dividend for the first quarter of 2024 of $1.30 per share on outstanding common stock. The dividend is payable on March 8, 2024 to shareholders of record at the close of business on Feb. 15, 2024.

Lilly Announces 15% Dividend Increase, First-Quarter 2024 Dividend

Novo Nordisk

Novo Nordisk and Eli Lilly have pulled ahead in the race for a slice of the weight-loss drugs market, expected to be worth $100 billion by the end of the decade, and rivals are looking to catch up through acquisitions and trials.

Novo, Lilly rivals explore booming weight-loss drug market entry

Novo Nordisk was first to market with its blockbuster weight loss treatment Wegovy. Doctors have prescribed Eli Lilly's diabetes treatment for weight loss.

Could Eli Lilly Beat Novo Nordisk in the Billion-Dollar Weight Loss Market?

Oracle

While the benchmark S&P 500 index is up nearly 20% since the start of this year, the equal-weight version of the index is only up 6.2%. This is because the Magnificent 7 stocks, Alphabet (NASDAQ: GOOG , NASDAQ: GOOGL ), Amazon (NASDAQ: AMZN ), Apple (NASDAQ: AAPL ), Meta Platforms (NASDAQ: META ), Microsoft (NASDAQ: MSFT ), Nvidia (NASDAQ: NVDA ) and Tesla (NASDAQ: TSLA ), continue to play a major role in the 2023 bull run.

Challenging the Magnificent 7: 3 Stocks on the Rise

Schwab U.S. Large-Cap Growth ETF

Vanguard Growth ETF

Large-cap growth stocks have been major drivers of total stock market returns over the past century. This fact has driven a sharp rise in the popularity of large-cap growth ETFs over the past two decades.

Better Large-Cap Growth Fund: Schwab U.S. Large-Cap Growth or Vanguard Growth Index Fund?

Eli Lilly used to trade at no higher than 30 times earnings, but those days appear to be long gone. Investors are paying a big premium for the stock due to its highly effective weight-loss treatment.

Should You Buy Eli Lilly Stock Now or Wait for a Dip?

Eli Lilly's drug serves as an alternative to rival obesity drugs such as Wegovy that are still facing supply issues.

Eli Lilly weight loss drug Zepbound now available at pharmacies as rival Wegovy faces shortages

Eli Lilly and Co (NYSE:LLY) announced that its weight loss drug Zepbound is now available at pharmacies in the US, sending its shares slightly higher Tuesday.  The treatment is expected to cost $25 per month for customers whose insurance covers the drug and $550 per month for customers whose insurance does not.

Eli Lilly's weight loss drug Zepbound is now available at US pharmacies

Results from MONARCH 3 show a numerical improvement in overall survival (OS) of 13.1 months for women with HR+, HER2- metastatic breast cancer treated with Verzenio plus an aromatase inhibitor in the intent-to-treat population and 14.9 months for women with visceral disease, however OS outcomes were not statistically significant Additional analyses of Verzenio in metastatic and early breast cancer, as well as imlunestrant (oral SERD) in combination with Verzenio, will be presented at the meeting INDIANAPOLIS , Dec. 5, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from the MONARCH 3 clinical trial, which will be presented in a late-breaking presentation during the 2023 San Antonio Breast Cancer Symposium (SABCS). MONARCH 3 evaluated Verzenio® (abemaciclib) in combination with an aromatase inhibitor (AI) compared to an AI alone as initial endocrine-based therapy for post-menopausal patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer.

Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer Symposium

Eli Lilly's recently approved obesity drug Zepbound is now available in U.S. pharmacies and could be available to some insured customers at $550 per month or half of the list price, the U.S. drugmaker said on Tuesday.

Eli Lilly's obesity drug now available in U.S. pharmacies

Eli Lilly & Co. LLY, +0.28% said Tuesday its new obesity drug Zepbound has been added to a major pharmacy benefit manager's preferred formulary, or list of covered drugs, as it hits U.S. pharmacy shelves. Zepbound, which was approved by the U.S. Food and Drug Administration last month, as of Dec. 1 was added to the preferred formulary of Express Scripts, the giant PBM owned by Cigna Group CI, -2.28%, and will be added to Cigna Healthcare commercial formularies as of Dec. 15, Lilly said.

Eli Lilly's new obesity drug Zepbound added to major PBM formularies as it hits pharmacy shelves

Express Scripts to add Zepbound to National Preferred Formulary INDIANAPOLIS , Dec. 5, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Zepbound™ (tirzepatide) injection is now available. Zepbound is indicated for adults with obesity (with a BMI of 30 kg/m2 or greater), or those who are overweight (with a BMI of 27 kg/m2 or greater) and also have weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease, to lose weight and keep it off.

News for Eli Lilly Stock (LLY)